Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

pirtobrutinib 5Tacrolimus 3Rituximab 3Mycophenolic Acid 3Cyclophosphamide 3venetoclax 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Busulfan 2Bendamustine Hydrochloride 2zanubrutinib 1isatuximab 1idelalisib 1ibrutinib 1acalabrutinib 1Vorinostat 1Ustekinumab 1Transplantation Conditioning 1Methotrexate 1Lenalidomide 1Interleukin-12 Subunit p40 1Immunoglobulin G 1Geriatric Assessment 1Disulfides 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Diseases × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡